Four-Drug cocktail aims to halt smoldering myeloma before it strikes
NCT ID NCT04775550
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This phase 2 trial tests whether a combination of four drugs—daratumumab, bortezomib, lenalidomide, and dexamethasone—can stop high-risk smoldering multiple myeloma from progressing to active multiple myeloma. Participants must be 18 or older and meet specific high-risk criteria. The study measures how many patients achieve minimal residual disease (MRD) negativity, meaning no cancer cells are detectable in the bone marrow.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
daratumumab, bortezomib, lenalidomide, and dexamethasone
What this could lead to
If successful, this combination could prevent or delay smoldering multiple myeloma from progressing to active multiple myeloma, potentially reducing the need for more intensive treatments later.
What could go wrong
This is a phase 2 trial with only 61 participants, so results may not apply to everyone. The drugs can cause side effects like infections, nerve damage, and blood clots, and the combination may not work for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AMPLIFI: Web-Based Lifestyle Program for Cancer NCT04000880
- BAFF CAR-T for Blood Cancers Trial NCT07679919
- Belantamab Mafodotin for Myeloma with Kidney Iss NCT04398745
- CAR T Cell Therapy for Multiple Myeloma Trial NCT03271632
- Isa-VRd for Multiple Myeloma in Transplant-Ineli NCT07663253
- DXC006 for Advanced Cancers: Phase 1 Trial (NCT06224855)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Dana-Farber Brigham Cancer Center
South Weymouth, Massachusetts, 02190, United States
-
Dana-Farber Brigham Cancer Center - Foxborough
Foxborough, Massachusetts, 02035, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute - Merrimack Valley
Methuen, Massachusetts, 01844, United States
-
Stamford Hospital
Stamford, Connecticut, 06902, United States